MAP Pharma Investor Sues To Stop Allergan's $958M Buy
A MAP Pharmaceuticals Inc. shareholder launched a putative class action Thursday in Delaware challenging Allergan Inc.'s proposed $958 million purchase of the company, saying the deal stiffs investors just as MAPP's...To view the full article, register now.
Already a subscriber? Click here to view full article